BridgeMD
New treatment option for Transcranial Alternating Current Stimulation
Official title Intervention Effect of High-Definition Transcranial Alternating Current Stimulation (HD-tACS) on Non-suicidal Self-injury (NSSI)
ClinicalTrials.gov ID: NCT06127056
What this study is testing
- What it's testing
- To investigate the intervention effect of high-definition transcranial alternating current stimulation (HD-tACS) on patients with Non-suicidal Self-injury (NSSI) and its underlying neural mechanism by magnetic resonance imaging (MRI).
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 12 to 18
You may be able to join if
- The patients were diagnosed by 2 or more senior clinical psychiatrists, meeting DSM-V criteria, and having 1 or more non-suicidal self-injurious...
- 12-18 years of age.
- The medicine has not changed in the 4 weeks prior to or after this study, and if it has to be changed, the treatment medication is required to be at...
You likely can't join if
- The patient has suicidal ideation or has committed suicidal behavior
- T1 or T2 weighted phase magnetic resonance images show focal brain lesions
- patients had neurological disorders such as epilepsy, or serious physical illnesses
- patients had a history of substance abuse and drug dependence in the last 6 months or use of anticonvulsant drugs in the last 3 months
- patients had received radial cranial electrical stimulation or magnetic stimulation treatment in the last 3 months or received electroconvulsive...
- patients had previous significant head trauma or EEG abnormality in the last 1 month
See the full eligibility criteria
- The patients were diagnosed by 2 or more senior clinical psychiatrists, meeting DSM-V criteria, and having 1 or more non-suicidal self-injurious behaviors in the last 6 months.
- 12-18 years of age.
- The medicine has not changed in the 4 weeks prior to or after this study, and if it has to be changed, the treatment medication is required to be at a subtherapeutic dosage level.
- The patient has suicidal ideation or has committed suicidal behavior
- T1 or T2 weighted phase magnetic resonance images show focal brain lesions
- patients had neurological disorders such as epilepsy, or serious physical illnesses
- patients had a history of substance abuse and drug dependence in the last 6 months or use of anticonvulsant drugs in the last 3 months
- patients had received radial cranial electrical stimulation or magnetic stimulation treatment in the last 3 months or received electroconvulsive therapy in the last 6 months
- patients had previous significant head trauma or EEG abnormality in the last 1 month
- body-mounted devices unsuitable for treatment, such as pacemakers, artificial valves, and other metal implants.
The study team makes the final eligibility decision.
Where it's taking place
- Hefei, Anhui, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 12 years to 18 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Hefei, Anhui, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.